SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio | N/A |
| Overall | INSUFFICIENT DATA |
$1.6B
19.83
2.244
2
$871.0K
9.01
0.3%
13
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($10.00, 2 analysts) | |||
| 10 | $85.80 | +$14.20 (17%) | 1.1R |
| 50 | $429.00 | +$71.00 (17%) | 1.1R |
| 100 | $858.00 | +$142.00 (17%) | 1.1R |
- High beta (2.24) — amplifies market moves by 2.24x
- Elevated short interest (9.01 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| VOYG | 0.298 |
| KRMN | 0.296 |
| BETA | 0.294 |
| SHAW.L | 0.264 |
| RDW | 0.230 |
| Ticker | Correlation |
|---|---|
| 003550.KS | -0.164 |
| BNO | -0.158 |
| USO | -0.158 |
| MCLDF | -0.138 |
| CF | -0.137 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.